GRO Biosciences Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 16
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $25M
Latest Deal Amount
  • Investors
  • 14

GRO Biosciences General Information

Description

Operator of a protein therapeutics technology platform intended to develop improved protein therapeutics across multiple disease classes including diabetes, growth disorders and autoimmunity. The company's platform is leveraging technologies from computational protein design and synthetic biology and has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins, enabling the proteins to have increased potency, stability and targeted delivery.

Contact Information

Website
www.grobio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 700 Main Street North
  • LabCentral
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

GRO Biosciences Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GRO Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 03-Nov-2021 $25M 000.00 000.00 Completed Generating Revenue
4. Seed Round 13-Mar-2019 00.000 00.000 000.00 Completed Startup
3. Grant 01-Feb-2019 00000 00.00 Completed Startup
2. Seed Round 16-Aug-2017 $2.4M $2.4M 00.00 Completed Startup
1. Accelerator/Incubator 13-Oct-2016 Completed Startup
To view GRO Biosciences’s complete valuation and funding history, request access »

GRO Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed-1 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 5,165,729 $0.000010 8% $0.46 $0.46 1x $0.46 7.78%
To view GRO Biosciences’s complete cap table history, request access »

GRO Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a protein therapeutics technology platform intended to develop improved protein therapeutics across multiple
Biotechnology
Cambridge, MA
16 As of 2021
000.00
00.00 0000-00-00
00000000000 000.00

000000 0

strud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in
0000 000000000
Menlo Park, CA
0 As of 0000
00.00
00.00 0000-00-00
000000&0 00.00

00000000

i ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000000000000
Bedford, MA
000 As of 0000
00000
0000 0000-00-00
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GRO Biosciences Competitors (75)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
xCella Biosciences Formerly VC-backed Menlo Park, CA 0 00.00 000000&0 00.00
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
0000000 Venture Capital-Backed Beijing, China 000 00000 00000000000 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
0000000 0000000000 Formerly VC-backed Berkeley, CA 00 00000 00000000 00000
You’re viewing 5 of 75 competitors. Get the full list »

GRO Biosciences Patents

GRO Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210369818-A1 Human dnase for lung disease Pending 19-Nov-2018 0000000000
CA-3106157-A1 Non-standard amino acid containing compositions and uses thereof Pending 09-Jul-2018 00000000
EP-3821003-A1 Non-standard amino acid containing compositions and uses thereof Pending 09-Jul-2018 00000000
JP-2021531037-A Non-standard amino acid-containing compositions and their use Pending 09-Jul-2018 00000000
US-20210371838-A1 Non-standard amino acid containing compositions and uses thereof Pending 09-Jul-2018 C12N9/22
To view GRO Biosciences’s complete patent history, request access »

GRO Biosciences Executive Team (7)

Name Title Board Seat Contact Info
Daniel Mandell Co-Founder, Chief Executive Officer & Board Member
Ross Thyer Ph.D Co-Founder & Advisor
Andrew Ellington Ph.D Co-Founder
George Church Co-Founder
Christopher Gregg Co-Founder, Chief Scientific Officer & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

GRO Biosciences Board Members (7)

Name Representing Role Since
Bruce Beutel Ph.D GRO Biosciences Board Member 000 0000
Christopher Gregg Self Co-Founder, Chief Scientific Officer & Board Member 000 0000
Daniel Mandell GRO Biosciences Co-Founder, Chief Executive Officer & Board Member 000 0000
Dror Berman Self Board Member 000 0000
Geoffrey Smith JD Digitalis Ventures Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

GRO Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GRO Biosciences Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alumni Ventures Venture Capital Minority 000 0000 000000 0
Leaps by Bayer Corporate Venture Capital Minority 000 0000 000000 0
Redmile Group Hedge Fund Minority 000 0000 000000 0
Dreamers VC Venture Capital Minority 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »